CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Kenya faces a significant disease burden that costs the country a lot of money. According to the National Aids and STIs Control Programme, over 1.4 million people live with HIV/Aids in Kenya.

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the ...